Evolus Announces Results from European Head-to-Head Filler Trial
- Evolus dermal filler product (Evolysse™/Estyme® Lift) demonstrates statistical superiority at 3 and 6 months compared to Restylane-L with respect to improvement in nasolabial fold severity
- The European Lift study met the primary endpoint of non-inferiority
Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025. The filler line will be branded Evolysse™ in the US and Estyme® in the
The European Lift study was blinded, randomized, 9 months in duration, and enrolled 45 patients. The study was a split face design, in which each patient received Estyme® Lift on one side and the control, Restylane-L, on the other side. Using a validated 5-point scale, the change in Nasolabial Fold (NLF) severity from baseline was measured. The primary endpoint of non-inferiority was met at 4 weeks, with the results favoring Estyme® Lift, and at 3 and 6 months, Estyme® Lift achieved statistical superiority over Restylane-L. The safety profiles were similar and there were no treatment related serious adverse events.
“The Evolysse™/Estyme® product line is the first filler made with the proprietary Cold-HA manufacturing process which is designed to better preserve the natural structure of the HA molecule, the building block for the entire line of fillers,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. “Lift represents one of the first Evolysse™ fillers that we will introduce in the US, and we believe this data is supportive of the performance benefits of the technology.”
“As the lead investigator in the US NLF trial, I have had first-hand experience injecting Evolysse™ Lift,” said Dr. Michael Kaminer, MD. “The product is extremely versatile and forgiving, with the unique property of being injectable at various depths in the skin. Post injection recovery was rapid, and the product has a nice ability to retain a 1:1 correction, providing both longevity and stable outcomes. The natural quality of the post-treatment aesthetic results with Evolysse™ Lift are impressive.”
In 2023 Evolus entered into two agreements with Symatese to be the exclusive distributor of a novel dermal filler line in late-stage development, the first agreement for
To participate in the fourth quarter earnings conference call, dial (877) 407-6184 (
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive
Jeuveau®, Nuceiva®, and Evolysse™ are trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301797950/en/
Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
